Dianthus Therapeutics Inc（DNTH）の財務DNTHDianthus Therapeutics Inc

Evaluating the bottom line, Dianthus Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8079.11%, while the net margin is -6598.55%. These profitability ratios, combined with a Return on Equity (ROE) of -26.07%, provide a clear picture of how effectively DNTH converts its operational activities into shareholder value.

In the context of the broader market, DNTH competes directly with industry leaders such as EWTX and TLX. With a market capitalization of $4.17B, it holds a significant position in the sector. When comparing efficiency, DNTH's gross margin of 100.00% stands against EWTX's N/A and TLX's 52.15%. Such benchmarking helps identify whether Dianthus Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Dianthus has a gross margin of 100% and a current ratio of 26.10, indicating strong liquidity. However, it has reported consistent net losses, with a net income of -50,215,000 USD in Q2 2026, which raises concerns about its profitability.